DE69919869D1 - Stimulierung des immunsystems - Google Patents

Stimulierung des immunsystems

Info

Publication number
DE69919869D1
DE69919869D1 DE69919869T DE69919869T DE69919869D1 DE 69919869 D1 DE69919869 D1 DE 69919869D1 DE 69919869 T DE69919869 T DE 69919869T DE 69919869 T DE69919869 T DE 69919869T DE 69919869 D1 DE69919869 D1 DE 69919869D1
Authority
DE
Germany
Prior art keywords
receptors
stimulation
immune system
inhibitor
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69919869T
Other languages
English (en)
Other versions
DE69919869T2 (de
Inventor
Karl-Hermann Schlingensiepen
Reimar Schlingensiepen
Wolfgang Brysch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biognostik Gesellschaft fuer Biomolekulare Diagnostik mbH
Original Assignee
Biognostik Gesellschaft fuer Biomolekulare Diagnostik mbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biognostik Gesellschaft fuer Biomolekulare Diagnostik mbH filed Critical Biognostik Gesellschaft fuer Biomolekulare Diagnostik mbH
Application granted granted Critical
Publication of DE69919869D1 publication Critical patent/DE69919869D1/de
Publication of DE69919869T2 publication Critical patent/DE69919869T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Electrotherapy Devices (AREA)
DE69919869T 1998-06-10 1999-06-10 Stimulierung des immunsystems Expired - Lifetime DE69919869T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP98110709 1998-06-10
EP98110709 1998-06-10
EP98113974 1998-07-25
EP98113974 1998-07-25
PCT/EP1999/004013 WO1999063975A2 (en) 1998-06-10 1999-06-10 A method for stimulating the immune system

Publications (2)

Publication Number Publication Date
DE69919869D1 true DE69919869D1 (de) 2004-10-07
DE69919869T2 DE69919869T2 (de) 2005-09-29

Family

ID=26149338

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69919869T Expired - Lifetime DE69919869T2 (de) 1998-06-10 1999-06-10 Stimulierung des immunsystems

Country Status (9)

Country Link
US (1) US8629117B2 (de)
EP (1) EP1089764B1 (de)
JP (1) JP4627369B2 (de)
AT (1) ATE274923T1 (de)
AU (1) AU5154999A (de)
CA (1) CA2334960C (de)
DE (1) DE69919869T2 (de)
ES (1) ES2226414T3 (de)
WO (1) WO1999063975A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884787B2 (en) 2001-07-14 2005-04-26 Isis Pharmaceuticals, Inc. Antisense modulation of transforming growth factor-beta 3 expression
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6436909B1 (en) * 1999-09-17 2002-08-20 Isis Pharmaceuticals, Inc. Antisense inhibition of transforming growth factor-β expression
EP1133994A1 (de) 2000-03-11 2001-09-19 Biognostik Gesellschaft für biomolekulare Diagnostik mbH Verfahren zür Umwandlung des immunosuppresive effekts von MIA (Melanoma Inhibitory Activity)
EP1191097A1 (de) * 2000-09-21 2002-03-27 Leids Universitair Medisch Centrum Induktion von "exon-skipping" in eukaryotischen Zellen
IL160157A0 (en) 2001-08-17 2004-07-25 Coley Pharm Group Inc Combination motif immune stimulation oligonucleotides with improved activity
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
DK2284266T3 (da) * 2002-11-14 2014-01-13 Thermo Fisher Scient Biosciences Inc sIRNA-MOLEKYLE MOD TP53
WO2004053104A2 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5’ cpg nucleic acids and methods of use
EP1444989A1 (de) 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensibilisierung von Zellen für die Apoptose durch selektive Blockade von Zytokinen
HUE030913T2 (en) * 2003-12-19 2017-06-28 Autotelic Llc A TGF-beta antagonist is a combination therapy associated with a chemotherapeutic agent
EP2248895B8 (de) 2003-12-19 2016-09-21 Autotelic LLC Kombinations-therapie die ein TGF-beta Antagonisten mit einem Chemotherapeutikum assoziiert
MXPA06009794A (es) * 2004-02-27 2007-03-15 Antisense Pharma Gmbh Composicion farmaceutica.
EP1568383A3 (de) * 2004-02-27 2005-11-16 Antisense Pharma GmbH Verwendung eines Oligonukleotide oder seiner aktiven Ableitung für die Zubereitung einer pharmazeutische Zusammensetzung zur Hemmung der Metastasenbildung in Krebsbehandlung
WO2005110464A2 (en) * 2004-05-14 2005-11-24 Oregon Health & Science University Irx5 inhibition as treatment for hyperproliferative disorders
US7893244B2 (en) 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
EP1877065A4 (de) 2005-04-12 2010-12-22 Intradigm Corp Zusammensetzung und verfahren mit rnai-therapeutika zur behandlung von krebs und anderen gefässneubildungserkrankungen
CA2591586A1 (en) 2005-05-05 2006-11-09 Antisense Pharma Gmbh Dosage of oligonucleotides
AU2005337776B2 (en) * 2005-10-24 2013-01-31 Proyecto De Biomedicina Cima, S.L. Use of TGF-Beta1 inhibitor peptides in the preparation of an immune response modulating agent
CN101896186A (zh) 2007-10-26 2010-11-24 莱顿教学医院 对抗肌肉病症的方式和方法
USRE48468E1 (en) 2007-10-26 2021-03-16 Biomarin Technologies B.V. Means and methods for counteracting muscle disorders
EP2119783A1 (de) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Verfahren für effizientes Exon (44)-Skipping bei Duchenne-Muskeldystrophie und entsprechende Mittel
US8822425B2 (en) 2008-11-14 2014-09-02 Antisense Pharma Gmbh Dosage of oligonucleotides suitable for the treatment of tumors
WO2010055148A2 (en) * 2008-11-14 2010-05-20 Antisense Pharma Gmbh Dosage of oligonucleotides suitable for the treatment of tumors
CN102712925B (zh) * 2009-07-24 2017-10-27 库尔纳公司 通过抑制sirtuin(sirt)的天然反义转录物来治疗sirtuin(sirt)相关性疾病
WO2011154542A1 (en) 2010-06-11 2011-12-15 Artisense Pharma Gmbh Method for selective oligonucleotide modification
WO2012015775A2 (en) 2010-07-28 2012-02-02 Dharmacon, Inc. Sirna targeting vegfa and methods for treatment in vivo
EP2453017A1 (de) * 2010-11-12 2012-05-16 Antisense Pharma GmbH Oligonucleotide zur Verwendung bei der Prophilaxe und/oder Behandlung von TGF-beta1- und TGF-beta2-, TGF-beta2- und TGF-beta3-, TGF-beta1- und TGF-beta3- oder TGF-beta1-, TGF-beta2- und TGF-beta3-mRNA-Überexpressionskrankheiten
EP4043039A1 (de) 2012-01-27 2022-08-17 BioMarin Technologies B.V. Rna-modulierende oligonukleotide mit verbesserten eigenschaften zur behandlung der duchenne- und becker-muskeldystrophie
KR101843984B1 (ko) 2016-02-09 2018-03-30 오토텔릭 엘엘씨 췌장암을 치료하기 위한 조성물과 방법
US9758786B2 (en) 2016-02-09 2017-09-12 Autotelic, Llc Compositions and methods for treating pancreatic cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2738392A (en) 1991-11-11 1993-05-13 Ciba-Geigy Ag Novel hybrid transforming growth factors
US5523389A (en) 1992-09-29 1996-06-04 Isis Pharmaceuticals, Inc. Inhibitors of human immunodeficiency virus
IL108367A0 (en) 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
JP3555952B2 (ja) * 1993-04-30 2004-08-18 バイオグノスティック・ゲゼルシャフト・フュア・バイオモレキュラーレ・ダイアグノスティック・ミット・ベシュレンクテル・ハフツング トランスフォーミング成長因子−β（ＴＧＦ‐β）の免疫抑制効果の治療用アンチセンス−オリゴヌクレオチド類
AU7053894A (en) 1993-06-09 1995-01-03 Ribozyme Pharmaceuticals, Inc. Enzymatic rna molecules and their application in the treatment of fibrosis and fibrous tissue disease
WO1995000103A2 (en) * 1993-06-15 1995-01-05 Il-Yang Pharm. Co., Ltd. Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
US5731294A (en) 1993-07-27 1998-03-24 Hybridon, Inc. Inhibition of neovasularization using VEGF-specific oligonucleotides
US5772995A (en) * 1994-07-18 1998-06-30 Sidney Kimmel Cancer Center Compositions and methods for enhanced tumor cell immunity in vivo
US6045802A (en) * 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
CA2251945A1 (en) 1996-04-17 1997-10-23 Aronex Pharmaceuticals, Inc. Antisense inhibitors of vascular endothelial growth factor (vefg/vpf) expression
JPH1052285A (ja) 1996-05-23 1998-02-24 Toagosei Co Ltd アンチセンス核酸の調製方法
JP4320054B2 (ja) * 1996-08-13 2009-08-26 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド ポリヌクレオチド送達のための組成物および方法
EP0968430A1 (de) 1997-03-07 2000-01-05 Mount Sinai Hospital Corporation Verfahrens zur diagnose einer benötigten regulierung der trophoblastinvasion
EP0945507A1 (de) 1998-03-27 1999-09-29 Boehringer Mannheim Gmbh Tumorspezifische Expressionskontrollregion und deren Verwendung

Also Published As

Publication number Publication date
DE69919869T2 (de) 2005-09-29
AU5154999A (en) 1999-12-30
US8629117B2 (en) 2014-01-14
WO1999063975A3 (en) 2000-08-03
CA2334960A1 (en) 1999-12-16
US20080124301A1 (en) 2008-05-29
EP1089764A2 (de) 2001-04-11
JP2002517434A (ja) 2002-06-18
ES2226414T3 (es) 2005-03-16
EP1089764B1 (de) 2004-09-01
ATE274923T1 (de) 2004-09-15
JP4627369B2 (ja) 2011-02-09
WO1999063975A2 (en) 1999-12-16
CA2334960C (en) 2012-01-03

Similar Documents

Publication Publication Date Title
DE69919869D1 (de) Stimulierung des immunsystems
FR2679914B1 (fr) Composition de caoutchouc de la serie des dienes connjuguees.
DK0817847T3 (da) IL-17-receptor
MXPA02001911A (es) Anticuerpos ctla-4 humanos y sus usos.
NL1003300A1 (nl) Implanteerbare therapeutische inrichting.
CY1106234T1 (el) Συνθεσεις για τη θepαπεια μολυνσεων staphylococcus aureus
NZ312327A (en) Controlling hemipteran insect pests with bacillus thuringiensis
FR2805465B1 (fr) Nouvelles compositions pharmaceutique ou dietetiques a base de champignons
ATE253351T1 (de) Desodoriende zubereitungen enthaltend wasserlösliche -(1,3)-glucane
GR1002768B (el) Δηλητηριασμενα δολωματα για τον ελεγχο των επιβλαβων εντομων.
PT932613E (pt) Expressao de bloqueio de factoes de virulencia em s. aureus
DE69102464D1 (de) Insektizide Zusammensetzung auf Basis von Bacillus Thuringiensis.
DK0983361T3 (da) Bakterielle pheromoner og anvendelser deraf
IT9048066A0 (it) 2- amminotetraline-6, 7-sostituite attive come immunomodulanti e composizioni farmaceutiche che le contengono.
ATE255594T1 (de) Hepatitis b inhibitoren
BR0009221A (pt) Vetores virais de inseto e usos dos mesmos
ITRM960096V0 (it) Dispositivo per il trattamento del corpo umano.
FR2708855B1 (fr) Compositions pharmaceutiques immunoadjuvantes ou immunostimulantes.
IT239134Y1 (it) Dispositivo aspirante, particolarmente per w.c.
UA33424A (uk) Пристрій для профілактики та лікування постмастектомічного синдрому
ES1036757Y (es) Dispositivo de engarce de dos piezas por simple presion para el montaje de estanterias.
IT1290938B1 (it) Complesso di sostanze naturali ad azione antiradicali liberi, sinergizzato da melatonina come antiossidante.
ITFI920015A1 (it) Dispositivo di elettrostimolazione particolarmente per applicazioni medicali e simili.
ITBO940195A0 (it) Dispositivo per uccidere insetti volanti.
TH14994EX (th) สารเสริมฤทธิ์ทางอิมมูนและสารป้องกันการติดเชื้อ

Legal Events

Date Code Title Description
8364 No opposition during term of opposition